Gain Therapeutics
GANX
42 hedge funds and large institutions have $15.8M invested in Gain Therapeutics in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 15 closing their positions.
402% more call options, than puts
Call options by funds: $502K | Put options by funds: $100K
1.55% less ownership
Funds ownership: 20.95% → 19.4% (-1.6%)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
13% less funds holding
Funds holding: 48 → 42 (-6)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
39% less capital invested
Capital invested by funds: $25.9M → $15.8M (-$10.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$635K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$303K |
| 3 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$286K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$234K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$551K |
| 2 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$251K |
| 3 |
HF
HRT Financial
New York
|
-$179K |
| 4 |
Jones Financial Companies
Des Peres,
Missouri
|
-$154K |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$120K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Millennium Management
New York
| – | -$45.1K | -14,002 | Closed |
|
|
SI
52
Sprott Inc
Toronto,
Ontario, Canada
| – | -$38.6K | -12,000 | Closed |
|
|
MCM
53
MAI Capital Management
Independence,
Ohio
| – | -$14.2K | -4,410 | Closed |
|
54
Bank of America
Charlotte,
North Carolina
| – | -$12.6K | -3,908 | Closed |
|
55
BNP Paribas Financial Markets
Paris,
France
| – | -$7.67K | -2,381 | Closed |
|
|
FIA
56
FNY Investment Advisers
New York
| – | -$6K | -2,000 | Closed |
|
|
SOW
57
State of Wyoming
Cheyenne,
Wyoming
| – | -$4.63K | -1,438 | Closed |
|
GANX Hedge Fund Activity: Q1 2026 in Review
42 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q1 2026, worth a combined $15.8M — down 39% from $25.9M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of GANX and 10 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was GSA Capital Partners, adding an estimated $635K. The largest seller was Susquehanna International Group, cutting an estimated $551K.
- 42 institutional investors held Gain Therapeutics (GANX) as of Q1 2026, down from 48 in Q4 2025.
- Funds reported $15.8M of Gain Therapeutics stock for Q1 2026, down 39% quarter-over-quarter.
- 10 funds opened new Gain Therapeutics positions in Q1 2026 and 15 closed out, a net change of -5 holders.
- The largest Gain Therapeutics buyer in Q1 2026 was GSA Capital Partners, an estimated $635K added.
- The largest Gain Therapeutics seller in Q1 2026 was Susquehanna International Group, an estimated $551K sold.
Based on aggregated 13F filings for Q1 2026.